Can Long-Term Use of Priligy Cure Premature Ejaculation?

Long-term use of dapoxetine does not constitute a cure for premature ejaculation (PE). Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) specifically approved for the on-demand treatment of PE in adult men. It works by delaying ejaculation through modulation of serotonin neurotransmission in central neural pathways involved in ejaculatory control.

Clinical evidence shows that dapoxetine improves intravaginal ejaculatory latency time (IELT), reduces perceived distress, and enhances sexual satisfaction—both for individuals and their partners—when taken 1–3 hours before sexual activity. However, its effects are pharmacologic and transient: benefits cease once dosing stops, and no studies demonstrate disease-modifying or curative properties.

PE is a multifactorial condition influenced by biological, psychological, and interpersonal factors. While dapoxetine addresses the neurobiological component, it does not resolve underlying contributors such as performance anxiety, relationship dynamics, or comorbid conditions like depression or erectile dysfunction. Comprehensive management often requires integrated approaches—including behavioral therapy (e.g., the stop-start or squeeze techniques), psychosexual counseling, and, when indicated, treatment of coexisting medical issues.

Chronic daily SSRI use—unlike on-demand dapoxetine—is associated with significant side effects (e.g., sexual dysfunction, emotional blunting, discontinuation syndrome) and is not recommended for PE without careful risk–benefit assessment. Regulatory agencies approve dapoxetine exclusively for intermittent use; long-term continuous administration lacks safety and efficacy data and is not supported by current guidelines.

In summary, dapoxetine is an effective symptomatic treatment—not a definitive cure—for PE. Sustained improvement typically requires ongoing use alongside holistic, patient-centered care strategies tailored to individual etiology and psychosocial context.